Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

7.465 -0.175 (-2.29%)
Streaming Delayed Price Updated: 12:16 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Opening plenary session features latest fetal fraction amplification research 
From Myriad Genetics, Inc.
Via GlobeNewswire
Demystifying Myriad Genetics: Insights From 6 Analyst Reviews
Via Benzinga
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
Where Myriad Genetics Stands With Analysts
Via Benzinga
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Study showed online screening tool and patient education improved genetic testing completion rate 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
From Myriad Genetics, Inc.
Via GlobeNewswire
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore® 
From Myriad Genetics, Inc.
Via GlobeNewswire
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year Running 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
From Myriad Genetics, Inc.
Via GlobeNewswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
Via Benzinga
Exposures Fossil Fuels
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.